[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100320748":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":35,"responsibleParty":71,"collaborators":74,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":10,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"CHU de Quebec-Universite Laval","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sleeve gastrectomy diabetes",null,"70 Men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy",[13],"Procedure: Bariatric surgery",{"label":15,"type":10,"description":16,"interventionNames":10},"Control without obesity or diabetes","30 Men and women who are overweight (without obesity) and without diabetes",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Bariatric surgery","Sleeve gastrectomy",[9],[24],{"name":25,"affiliation":26,"role":27},"Claudia Gagnon, Dr","CHU de Québec - Université Laval","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Sarah Chouinard-Castonguay","CONTACT","4185254444","48729","Sarah.Chouinard-Castonguay@crchudequebec.ulaval.ca",[36,50,60],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"The Research Institute of the McGill University Health Centre","TERMINATED","Montreal","Quebec","H3H 2R9","Canada","CA",{"type":45,"coordinates":46},"Point",[47,48],-73.58781,45.50884,{"lat":48,"lon":47},{"facility":51,"status":52,"city":53,"state":40,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Centre de recherche du CHU de Québec - Université Laval","ACTIVE_NOT_RECRUITING","Québec","G1V 4G2",{"type":45,"coordinates":56},[57,58],-71.21454,46.81228,{"lat":58,"lon":57},{"facility":61,"status":62,"city":53,"state":40,"zip":63,"country":42,"countryCode":43,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Centre de recherche de l'IUCPQ","RECRUITING","G1V 4G5",{"type":45,"coordinates":65},[57,58],{"lat":58,"lon":57},[68,69],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},{"name":70,"role":27,"phone":10,"phoneExt":10,"email":10},"Gagnon Claudia, Dr",{"type":27,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Claudia Gagnon","Dr",[75],{"name":76,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","100320748","bone-health-after-bariatric-surgery-in-patients-with-type-2-diabetes-100320748",false,"NCT03455868","Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes","BODI","Inclusion Criteria:\n\n* bariatric groups: men and women; 18 to 60 years old; with a BMI \\>=35 kg\u002Fm2; with type 2 diabetes: use of oral hypoglycemic agents or insulin OR 2 of the following tests confirming type 2 diabetes: HbA1c \\>=6.5%; fasting glucose \\>=7.0 mM; 2-h glucose post 75g oral glucose tolerance test (OGTT) \\>=11.1 mM) (guidelines.diabetes.ca);) or without diabetes: HbA1c \\\u003C6.5% AND fasting glucose \\\u003C7.0 mM; who are awaiting bariatric surgery. Control group: BMI 25.0 to 29.9 kg\u002Fm2 (overweight group); without diabetes or prediabetes: HbA1c \\\u003C6.0% AND fasting glucose \\\u003C6.1 mM (Diabetes Canada criteria), with a stable weight for the last 3 months.\n\nExclusion Criteria:\n\n* bariatric groups: type 1 diabetes; disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance \\\u003C60 ml\u002Fmin) or medication (e.g. glucocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism; BMI\\>60 kg\u002Fm2; CT scan impossible to perform (e.g. patient too large for the gantry aperture); pregnant women or women who plan to become pregnant during the study or women of childbearing age who do not agree to take an appropriate contraceptive method during the study; history of oesophageal, gastric or digestive surgery; history of bariatric surgery; cancer at risk of recurrence during the study; Prosthesis that could interfere with interpretation of imaging data; Chronic severe condition or illness precluding from participation in the project.\n\nControl group: Same criteria plus: \\>5% change in weight in the last 3 months; pregnancy or lactation in the last year.",true,"ALL","18 Years","60 Years",{"count":89,"type":90},100,"ESTIMATED","OBSERVATIONAL","Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in patients with type 2 diabetes; (2) to compare vBMD and its potential determinants after bariatric surgery with obese controls without diabetes as well as with controls without obesity and normoglycemia.",[94,95,96,97],"Bariatric Surgery","Bone Health","Obesity, Morbid","Diabetes Mellitus, Type 2","2025-06-05",{"date":100,"type":101},"2025-06-10","ACTUAL",{"date":103,"type":101},"2018-03-15",{"date":105,"type":90},"2025-12-01",{"name":5,"class":6},3]